Trial
NCT04352205
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Janssen Scientific Affairs, LLC; National Cancer Institute (NCI)
Condition
Plasma Cell Myeloma
Intervention
Bortezomib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-01